Subgroup analysis based on sample type indicated that DAPK promoter methylation was significantly associated with the risk of GC in tissue subgroup, but not in blood subgroup, indicating that the use of DAPK promoter methylation as a noninvasive biomarker based on blood samples could not distinguish gastric cancer and nonmalignant samples. This evidence concerns the gene DAPK1 and gastric cancer.